- AstraZeneca to receive $270M on completion. The transaction is expected to be close in Q4’21 while Covis will also pay an ongoing development cost related to the therapy
- The acquisition will strengthen Covis’ respiratory portfolio with the addition of Eklira & Duaklir. Additionally, both therapies are delivered via a Genuair device that is used for the treatment of patients with COPD
- Eklira is marketed as Bretaris while Duaklir as Brimica in some countries & both are inhaled respiratory therapies. In 2018, Covis has previously acquired the rights from AstraZeneca to the respiratory medicines i.e., Alvesco, Omnaris, and Zetonna
Click here to read the full press release/ article | Ref: AstraZeneca | Image: Reuters
The post AstraZeneca to Divest Global Rights of Eklira and Duaklir to Covis Pharma in $270M Deal first appeared on PharmaShots.